insights_auto
Why is ABVX down 3,67%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
78,70 €
arrow_downward
-3,67%(-3,00) 1D
23-окт., 16:35:27 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
80,90 €
High
81,15 €
Low
78,05 €
Mkt. cap
6,82 млд
Avg. vol.
124,74 миң
Volume
0,00
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
80,90 €
High
81,15 €
Low
78,05 €
Mkt. cap
6,82 млд
Avg. vol.
124,74 миң
Volume
0,00
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
bloomingbit
·
1 саат мурун
Hong Kong Names Nasdaq-Listed Solana Company Strategic Enterprise to Support Blockchain Infrastructure
IBS Intelligence
·
28 мүнөт мурун
Nasdaq appoints Andrew Murray to lead Financial Technology in Singapore
www.marketscreener.com
·
20 мүнөт мурун
Three Companies on Nasdaq Stockholm Trade Ex-Dividend Today
Bloomberg.com
·
15 саат мурун
Zero-Day Option Traders Are Betting Against Big S&P 500 Swings
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
Sector-
Websiteabivax.com